Adaptation limits the efficacy of most clinical drug therapies and is also a form of synaptic plasticity, which is important in learning and memory.[1] Adaptation has been studied extensively with electrophysiology and biochemistry, but rarely with genetics. A genetic screen using C. elegans was recently described for defects in adaptation to serotonin and dopamine[2], which may occur at metabotropic (G-protein coupled) receptors. Many mutants were isolated from this screen, and the identity and biology of two mutants,
unc-2 and
unc-36, was described. While metabotropic receptors and ionotropic receptors (ion channels) are thought to share some mechanisms of adaptation, there are also important differences.[3] A genetic approach to adaptation at ionotropic receptors has not yet been reported. We have initiated a screen for mutants that fail to undergo adaptation to muscimol, an agonist of the ionotropic GABA-A receptor. Muscimol inhibits both body wall and pharyngeal muscle[4]. We used the rate of pharyngeal pumping as a quantitative measure of the degree of inhibition by muscimol. When incorporated into NG plates muscimol causes a dose- dependent decrease in the rate of pharyngeal pumping, reaching complete inhibition of pumping at 6mM. With wild type, pumping slowly increases after 1 hour, and reaches 80-90 percent of untreated after 4 hours. By visually screening mutagenized animals we have isolated 5 mutations that result in a significant reduction in pumping rate after a 3 hour muscimol exposure. The reduction is statistically significant but subtle, approximately 3-fold for all mutants. To rule out the possibility that the mutants are simply hypersensitive to muscimol, we examined dose-response curves of the mutants and wild type. None of the mutants is hypersensitive. Therefore, all five mutations presumably cause defects in adaptation at the ionotropic GABA-A receptor. Defects in adaptation to other neurotransmitters have not yet been examined. In parallel, we examined the previously characterized adaptation mutants
unc-2 and
unc-36 for possible effects on adaptation to muscimol. Both mutants regain their normal rates of pumping significantly more slowly than wild type on 6mM muscimol. This effect is particularly evident with
unc-36, which shows an approximately 15-fold reduction in adaptation to 6mM muscimol. However, the effects of
unc-2 on the presumed adaptation defect at the GABA-A receptor may be attributed to muscimol hypersensitivity. Low doses of muscimol that inhibit wild type pumping only 2 to 5 percent inhibit pumping in
unc-2 by about 45 percent. It is interesting that
unc-36, which encodes a Ca++ channel subunit, is defective in adaptation to several different neurotransmitter agonists. We speculate that calcium influx may be a shared first step in transmitter adaptation pathways. I. Huaginir, R.L. and Greengard, P. (1990) Neuron 5:555-567. 2. Schafer, W.R and Kenyon, C.J. (1995) Nature 375:73-78. 3. Lohse, M.J. (1993) Biochem et Biophys Acta 1179:171-188. Leidenheimer, N.J. et al. (1991), TIPS 12:84-87. Raymond, L.A. et al. (1993) TINS 16:147-153. 4. McIntire, S.L., Jorgensen, E. and Horvitz, R.H. (1993) Nature 364:334-337.